Vivos Therapeutics Inc. (VVOS): Price and Financial Metrics
GET POWR RATINGS... FREE!
VVOS Stock Price Chart Interactive Chart >
VVOS Price/Volume Stats
|Current price||$4.69||52-week high||$14.41|
|Prev. close||$4.65||52-week low||$2.61|
|Day high||$4.96||Avg. volume||1,324,664|
|50-day MA||$4.14||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||106.99M|
Vivos Therapeutics Inc. (VVOS) Company Bio
Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of technology solutions for patients with sleep disordered breathing (SDB) comprising mild-to-moderate obstructive sleep apnea (OSA). The company's solutions cover proprietary alternatives for treating mild-to-moderate OSA; craniofacial and anatomical anomalies that are associated with mild-to-moderate OSA. Its treatment for OSA involves specially designed and customized oral appliances and treatment protocols. The company, through its Vivos Integrated Healthcare Network, provides access to healthcare providers for delivering care for patients suffering from sleep disordered breathing, including mild-to-moderate OSA. Vivos Therapeutics, Inc. also licenses its intellectual property to third-party manufacturers, which fabricate appliance devices for healthcare professionals. It caters to general dentists, medical doctors, myofunctional therapists, chiropractors, healthcare providers, and patients in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2007 and is based in Highlands Ranch, Colorado.
Most Popular Stories View All
VVOS Latest News Stream
|Loading, please wait...|
VVOS Latest Social Stream
View Full VVOS Social Stream
Latest VVOS News From Around the Web
Below are the latest news stories about Vivos Therapeutics Inc that investors may wish to consider to help them evaluate VVOS as an investment opportunity.
Vivos management to present at 7:00 am EDT on September 13, 2021 HIGHLANDS RANCH, Colo., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (OSA) and snoring, today announced that Kirk Huntsman, Chief Executive Officer, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Confe
Investors need to pay close attention to Vivos (VVOS) stock based on the movements in the options market lately.
Vivos Therapeutics and Empower Sleep Launch Cooperative Relationship Aimed at Significantly Improving Proper Obstructive Sleep Apnea Diagnosis and Treatment
HIGHLANDS RANCH, Colo., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (OSA), today announced a new cooperative relationship with Empower Sleep, a San Bernardino, Calif.-based company empowering patients with affordable,
Good morning, investor!
Following the market opening Tuesday, the Dow traded up 0.11% to 35,374.12 while the NASDAQ rose 0.43% to 15,006.17. The S&P also rose, gaining 0.22% to 4,489.23. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 37,941,620 cases with around 629,560 deaths. India confirmed a total of at least 32,474,770 cases and 435,110 deaths, while Brazil reported over 20,583,990 COVID-19 cases with 574,840 deaths. In total, there were at least 212,639,390 case
VVOS Price Returns